Five latent patterns of immune checkpoint inhibitor-related adverse event reporting across cancer types: an integrated pharmacovigilance and transcriptomic analysis

Immune checkpoint inhibitor (ICI)-related adverse event (irAE) profiles vary across cancer types, but whether they form shared cross-cancer patterns remains unclear. We analyzed 200,099 ICI-exposed cancer reports from the US Food and Drug Administration Adverse Event Reporting System and 65,309 from the Japanese Adverse Drug Event Report database (2015-2025). Cancer-system organ class (SOC) reporting profiles were quantified by disproportionality analysis, and non-negative matrix factorization identified latent patterns. Pattern-defined cancer groups were characterized by organ-system involvement, fatal outcome reporting, and time to onset; FAERS-derived profiles were evaluated in JADER, and exploratory transcriptomic annotation used TCGA and GTEx data. FAERS showed heterogeneous cancer-specific reporting profiles (representative reporting odds ratios, 2.11-6.42; all P < 0.001), with major profiles reproduced in JADER. Five latent patterns were identified: ocular, hematologic, neurologic, systemic-like, and visceral-like. The visceral-like group, dominated by gastrointestinal, hepatobiliary, renal and urinary, and respiratory involvement, had the highest proportion of irAE reports with recorded fatal outcomes in FAERS (19.0%) and JADER (4.8%); in FAERS, its median onset was 34 days. Median onset in FAERS was earliest in the systemic-like group (32 days) and latest in the hematologic group (43 days; P < 0.001). At the cancer-type level, exploratory transcriptomic annotation showed broad immune activation in cancers of the systemic-like group and macrophage, dendritic-cell, bile acid metabolism, and cytokine-signaling features in cancers of the visceral-like group. The five-pattern framework organizes cross-cancer heterogeneity in relative organ-system irAE reporting profiles and provides hypotheses for cancer-informed safety surveillance and prospective biological investigation.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.1983531
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Five latent patterns of immune checkpoint inhibitor-related adverse event reporting across cancer types: an integrated pharmacovigilance and transcriptomic analysis

Bo Peng, Linghao Ni, Xue Min, Dingqian Yong et al.
4 links
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

Five latent patterns of immune checkpoint inhibitor-related adverse event reporting across cancer types: an integrated pharmacovigilance and transcriptomic analysis

Bo Peng, Linghao Ni, Xue Min, Dingqian Yong, Jiawei Zhou, Guohan Song, Xiaoyu Shan
article en

Abstract

Immune checkpoint inhibitor (ICI)-related adverse event (irAE) profiles vary across cancer types, but whether they form shared cross-cancer patterns remains unclear. We analyzed 200,099 ICI-exposed cancer reports from the US Food and Drug Administration Adverse Event Reporting System and 65,309 from the Japanese Adverse Drug Event Report database (2015-2025). Cancer-system organ class (SOC) reporting profiles were quantified by disproportionality analysis, and non-negative matrix factorization identified latent patterns. Pattern-defined cancer groups were characterized by organ-system involvement, fatal outcome reporting, and time to onset; FAERS-derived profiles were evaluated in JADER, and exploratory transcriptomic annotation used TCGA and GTEx data. FAERS showed heterogeneous cancer-specific reporting profiles (representative reporting odds ratios, 2.11-6.42; all P < 0.001), with major profiles reproduced in JADER. Five latent patterns were identified: ocular, hematologic, neurologic, systemic-like, and visceral-like. The visceral-like group, dominated by gastrointestinal, hepatobiliary, renal and urinary, and respiratory involvement, had the highest proportion of irAE reports with recorded fatal outcomes in FAERS (19.0%) and JADER (4.8%); in FAERS, its median onset was 34 days. Median onset in FAERS was earliest in the systemic-like group (32 days) and latest in the hematologic group (43 days; P < 0.001). At the cancer-type level, exploratory transcriptomic annotation showed broad immune activation in cancers of the systemic-like group and macrophage, dendritic-cell, bile acid metabolism, and cytokine-signaling features in cancers of the visceral-like group. The five-pattern framework organizes cross-cancer heterogeneity in relative organ-system irAE reporting profiles and provides hypotheses for cancer-informed safety surveillance and prospective biological investigation.

Frontiers in ImmunologyVol. 17
Chongqing Medical University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon